NAMPT and hepatocellular carcinoma: These results are in concordance with those of Shen et al., (2016), and in contrast with those of Sun et al., (2017) who reported that HCC patients with high serum visfatin levels had significantly shorter OS times compared to those with low serum visfatin levels.